Skye Bioscience Statistics

Total Valuation

Skye Bioscience has a market cap or net worth of $97.30 million. The enterprise value is $49.09 million.

Market Cap	97.30M
Enterprise Value	49.09M

Important Dates

The last earnings date was Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Skye Bioscience has 30.99 million shares outstanding. The number of shares has increased by 82.20% in one year.

Current Share Class	30.99M
Shares Outstanding	30.99M
Shares Change (YoY)	+82.20%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	1.57%
Owned by Institutions (%)	32.40%
Float	16.77M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.23
P/TBV Ratio	2.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.09, with a Debt / Equity ratio of 0.01.

Current Ratio	6.09
Quick Ratio	5.85
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -72.75% and return on invested capital (ROIC) is -46.79%.

Return on Equity (ROE)	-72.75%
Return on Assets (ROA)	-40.92%
Return on Invested Capital (ROIC)	-46.79%
Return on Capital Employed (ROCE)	-104.09%
Revenue Per Employee	n/a
Profits Per Employee	-$2.65M
Employee Count	16
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Skye Bioscience has paid $5,400 in taxes.

Income Tax	5,400
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.74% in the last 52 weeks. The beta is 2.21, so Skye Bioscience's price volatility has been higher than the market average.

Beta (5Y)	2.21
52-Week Price Change	-31.74%
50-Day Moving Average	3.40
200-Day Moving Average	3.04
Relative Strength Index (RSI)	39.64
Average Volume (20 Days)	350,030

Short Selling Information

The latest short interest is 2.71 million, so 8.74% of the outstanding shares have been sold short.

Short Interest	2.71M
Short Previous Month	2.68M
Short % of Shares Out	8.74%
Short % of Float	16.15%
Short Ratio (days to cover)	4.21

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-45.64M
Pretax Income	-42.28M
Net Income	-42.37M
EBITDA	-45.03M
EBIT	-45.64M
Earnings Per Share (EPS)	-$1.07

Full Income Statement

Balance Sheet

The company has $48.59 million in cash and $367,540 in debt, giving a net cash position of $48.22 million or $1.56 per share.

Cash & Cash Equivalents	48.59M
Total Debt	367,540
Net Cash	48.22M
Net Cash Per Share	$1.56
Equity (Book Value)	43.68M
Book Value Per Share	1.41
Working Capital	42.27M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$33.37 million and capital expenditures -$1.57 million, giving a free cash flow of -$34.94 million.

Operating Cash Flow	-33.37M
Capital Expenditures	-1.57M
Free Cash Flow	-34.94M
FCF Per Share	-$1.13

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Skye Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-82.20%
Shareholder Yield	-82.20%
Earnings Yield	-43.55%
FCF Yield	-35.91%

Analyst Forecast

The average price target for Skye Bioscience is $16.60, which is 428.66% higher than the current price. The consensus rating is "Buy".

Price Target	$16.60
Price Target Difference	428.66%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	33.63%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:250.

Last Split Date	Sep 8, 2023
Split Type	Reverse
Split Ratio	1:250

Scores

Altman Z-Score	n/a
Piotroski F-Score	2